Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Non-Current Assets (2023 - 2025)

Kura Oncology (KURA) has disclosed Other Non-Current Assets for 3 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 85.38% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, up 85.38% year-over-year, with the annual reading at $14.5 million for FY2025, 85.38% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $14.5 million at Kura Oncology, up from $13.8 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $14.5 million in Q4 2025, with the low at $210000.0 in Q1 2023.
  • Average Other Non-Current Assets over 3 years is $7.6 million, with a median of $7.8 million recorded in 2024.
  • Peak annual rise in Other Non-Current Assets hit 3550.48% in 2024, while the deepest fall reached 3.2% in 2024.
  • Over 3 years, Other Non-Current Assets stood at $7.6 million in 2023, then rose by 3.2% to $7.8 million in 2024, then soared by 85.38% to $14.5 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $14.5 million, $13.8 million, and $10.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.